Hologic, Inc. (NASDAQ:HOLX) has earned a consensus rating of “Buy” from the twenty analysts that are presently covering the company, Market Beat Ratings reports. Eight investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $42.39.

Shares of Hologic (NASDAQ:HOLX) opened at 33.94 on Tuesday. The stock has a 50 day moving average price of $37.05 and a 200 day moving average price of $38.85. Hologic has a 12 month low of $29.72 and a 12 month high of $43.00. The firm has a market capitalization of $9.63 billion and a P/E ratio of 53.03.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Wednesday, January 27th. The company reported $0.46 EPS for the quarter, topping analysts’ consensus estimates of $0.42 by $0.04. During the same quarter in the previous year, the business posted $0.39 earnings per share. The company earned $695.20 million during the quarter, compared to analyst estimates of $688.68 million. The company’s revenue for the quarter was up 6.5% compared to the same quarter last year. On average, analysts expect that Hologic will post $1.87 earnings per share for the current year.

In other Hologic news, Director Lawrence M. Levy sold 20,000 shares of the business’s stock in a transaction dated Tuesday, November 10th. The shares were sold at an average price of $40.70, for a total value of $814,000.00. Following the transaction, the director now directly owns 3,914 shares in the company, valued at $159,299.80. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

A number of hedge funds and institutional investors recently added to or reduced their stakes in HOLX. KBC Group boosted its position in Hologic by 40.8% in the third quarter. KBC Group now owns 11,621 shares of the company’s stock worth $455,000 after buying an additional 3,367 shares during the last quarter. Janus Capital Management boosted its stake in shares of Hologic by 1,359.1% in the third quarter. Janus Capital Management now owns 370,900 shares of the company’s stock worth $14,513,000 after buying an additional 345,480 shares during the last quarter. Curbstone Financial Management boosted its stake in shares of Hologic by 100.0% in the fourth quarter. Curbstone Financial Management now owns 13,806 shares of the company’s stock worth $534,000 after buying an additional 6,903 shares during the last quarter. Natixis Asset Management boosted its stake in shares of Hologic by 19.1% in the third quarter. Natixis Asset Management now owns 13,928 shares of the company’s stock worth $545,000 after buying an additional 2,231 shares during the last quarter. Finally, ID Management A boosted its stake in shares of Hologic by 33.3% in the fourth quarter. ID Management A now owns 16,400 shares of the company’s stock worth $635,000 after buying an additional 4,100 shares during the last quarter.

HOLX has been the subject of a number of research reports. JPMorgan Chase & Co. upgraded shares of Hologic from a “neutral” rating to an “outperform” rating in a report on Thursday, November 26th. Craig Hallum cut shares of Hologic from a “buy” rating to a “hold” rating and reduced their price target for the stock from $42.00 to $37.00 in a report on Wednesday, October 21st. William Blair restated a “buy” rating on shares of Hologic in a report on Tuesday, October 20th. Needham & Company LLC upgraded shares of Hologic from a “hold” rating to a “buy” rating and set a $41.00 price target for the company in a report on Thursday. Finally, Zacks Investment Research upgraded shares of Hologic from a “hold” rating to a “buy” rating and set a $45.00 price objective for the company in a report on Friday, November 6th.

Hologic, Inc. is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products. The Company’s business units are focused on diagnostics, breast health, GYN surgical and skeletal health. The Company’s diagnostics products include Aptima family of assays, its ThinPrep system, the Rapid Fetal Fibronectin Test and its Procleix blood screening assays. The Aptima family of assays is used to detect the infectious microorganisms that cause the common sexually transmitted diseases, chlamydia and gonorrhea, certain high-risk strains of human papillomavirus (NASDAQ:HOLX), and Trichomonas vaginalis, the parasite that causes trichomoniasis. The Company’s GYN surgical products include its NovaSure Endometrial Ablation System and its MyoSure Hysteroscopic Tissue Removal System. The skeletal health products include dual-energy X-ray bone densitometry systems, an ultrasound-based osteoporosis assessment product, and its Fluoroscan mini C-arm imaging products.

12 Month Chart for NASDAQ:HOLX

Frustrated with your broker? Are you tired of paying high fees? Do you feel like you are getting ripped off by your stock broker? It's time for a change. Find out which brokerage is best for your personal trading style at the InvestorPlace Broker Center. Compare brokers at a glance in the InvestorPlace Broker Center (Click Here).

Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.